{"id":1018312,"date":"2026-11-06T08:12:15","date_gmt":"2026-11-06T13:12:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/"},"modified":"2026-11-06T08:12:15","modified_gmt":"2026-11-06T13:12:15","slug":"engene-to-participate-in-upcoming-investor-conferences-6","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/","title":{"rendered":"enGene to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>enGene to Participate in Upcoming Investor Conferences<\/b><\/p>\n<p>BOSTON &amp; MONTREAL&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nenGene Therapeutics Inc. (Nasdaq: ENGN, \u201cenGene\u201d or the \u201cCompany\u201d), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:<\/p>\n<p><b>UBS Global Biopharma Conference 2026<br \/>\n<br \/><\/b><b>Date: <\/b>Monday, November 16, 2026<br \/>\n<br \/><b>Time: <\/b>3:20 p.m. GMT \/ 10:20 a.m. ET<br \/>\n<br \/><b>Format:<\/b> Fireside Chat<\/p>\n<p><b>Jefferies Global Healthcare Conference in London<br \/>\n<br \/><\/b><b>Date: <\/b>Thursday, November 19, 2026<br \/>\n<br \/><b>Time: <\/b>10:30 a.m. GMT \/ 5:30 a.m. ET<br \/>\n<br \/><b>Format: <\/b>Fireside Chat<\/p>\n<p>\nA live webcast of these events can be accessed on the \u201cEvents and Presentations\u201d page under the \u201cInvestors\u201d section of the enGene website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.engene.com&amp;esheet=54636482&amp;newsitemid=20261106948854&amp;lan=en-US&amp;anchor=www.engene.com&amp;index=1&amp;md5=4cab2d3298930fbbe3ae036a14310950\">www.engene.com<\/a> and will be archived there for 90 days.<\/p>\n<p><b>About enGene<\/b><\/p>\n<p>\nenGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene\u2019s lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease.<\/p>\n<p>\nDetalimogene was developed using enGene\u2019s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.<\/p>\n<p>\nTo learn more, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fengene.com%2F&amp;esheet=54636482&amp;newsitemid=20261106948854&amp;lan=en-US&amp;anchor=enGene.com&amp;index=2&amp;md5=5d57d27c709bd1137d4f550cf0b0c7c9\">enGene.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fengene%2F&amp;esheet=54636482&amp;newsitemid=20261106948854&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=69a578df5732d595cdcda8280ab9b84d\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2Fengene_inc&amp;esheet=54636482&amp;newsitemid=20261106948854&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=05919d0a1976d3a047abd36dc088c762\">X<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbsky.app%2Fprofile%2Fengeneinc.bsky.social&amp;esheet=54636482&amp;newsitemid=20261106948854&amp;lan=en-US&amp;anchor=BlueSky&amp;index=5&amp;md5=9f9a2793a5ca7069f815f3e58fdb4bbd\">BlueSky<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261106948854r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261106948854\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261106948854\/en\/<\/a><\/span><\/p>\n<p><b>Media and Investor Contact:<br \/>\n<\/b><br \/>Lauren Hopfer<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Lhopfer@engene.com\">Lhopfer@engene.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts North America United States United Kingdom Europe Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Genetics Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261106948854\/en\/2159786\/3\/enGene_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>enGene to Participate in Upcoming Investor Conferences BOSTON &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; enGene Therapeutics Inc. (Nasdaq: ENGN, \u201cenGene\u201d or the \u201cCompany\u201d), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: UBS Global Biopharma Conference 2026 Date: Monday, November 16, 2026 Time: 3:20 p.m. GMT \/ 10:20 a.m. ET Format: Fireside Chat Jefferies Global Healthcare Conference in London Date: Thursday, November 19, 2026 Time: 10:30 a.m. GMT \/ 5:30 a.m. ET Format: Fireside Chat A live webcast of these events can be accessed on the \u201cEvents and Presentations\u201d page under the \u201cInvestors\u201d section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene Therapeutics Inc. is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;enGene to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018312","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>enGene to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"enGene to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"enGene to Participate in Upcoming Investor Conferences BOSTON &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; enGene Therapeutics Inc. (Nasdaq: ENGN, \u201cenGene\u201d or the \u201cCompany\u201d), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: UBS Global Biopharma Conference 2026 Date: Monday, November 16, 2026 Time: 3:20 p.m. GMT \/ 10:20 a.m. ET Format: Fireside Chat Jefferies Global Healthcare Conference in London Date: Thursday, November 19, 2026 Time: 10:30 a.m. GMT \/ 5:30 a.m. ET Format: Fireside Chat A live webcast of these events can be accessed on the \u201cEvents and Presentations\u201d page under the \u201cInvestors\u201d section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene Therapeutics Inc. is a &hellip; Continue reading &quot;enGene to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T13:12:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261106948854r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"enGene to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-11-06T13:12:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/\"},\"wordCount\":314,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261106948854r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/\",\"name\":\"enGene to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261106948854r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-06T13:12:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261106948854r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261106948854r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-upcoming-investor-conferences-6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"enGene to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"enGene to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/","og_locale":"en_US","og_type":"article","og_title":"enGene to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"enGene to Participate in Upcoming Investor Conferences BOSTON &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; enGene Therapeutics Inc. (Nasdaq: ENGN, \u201cenGene\u201d or the \u201cCompany\u201d), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: UBS Global Biopharma Conference 2026 Date: Monday, November 16, 2026 Time: 3:20 p.m. GMT \/ 10:20 a.m. ET Format: Fireside Chat Jefferies Global Healthcare Conference in London Date: Thursday, November 19, 2026 Time: 10:30 a.m. GMT \/ 5:30 a.m. ET Format: Fireside Chat A live webcast of these events can be accessed on the \u201cEvents and Presentations\u201d page under the \u201cInvestors\u201d section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene Therapeutics Inc. is a &hellip; Continue reading \"enGene to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-06T13:12:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261106948854r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"enGene to Participate in Upcoming Investor Conferences","datePublished":"2026-11-06T13:12:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/"},"wordCount":314,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261106948854r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/","name":"enGene to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261106948854r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-06T13:12:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261106948854r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261106948854r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-upcoming-investor-conferences-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"enGene to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018312"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018312\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}